S23-252 Patient-derived organoids for evaluating immunotherapies against lymphoma Stanford scientists have developed lymphoma organoids derived from primary patient biopsies that recapitulate the tumor microenvironment. Arash Alizadeh Joseph Schroers-Martin Brian Sworder Maximilian Diehn Lisa Wagar Jenna Kastenschmidt
S21-461 Cell-type specific enzymatic degradation of pathological mucins Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies. Carolyn Bertozzi Kayvon Pedram Dayeon Shon Gabrielle Tender
S21-223 Blocking and Reversing Extracellular Vesicle-Driven Transcriptomic Transformation with Annexin V Treatment Stanford researchers led by Dr. Francis Blankenberg Derek Holman